



Claims

1. A glucopyranosyloxypyrazole derivative represented by the general formula:




5

wherein R^1 represents a hydrogen atom or a lower alkyl group; one of Q^1 and T^1 represents a group represented by the formula:




while the other represents a lower alkyl group or a halo(lower alkyl) group; R^2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a pharmaceutically acceptable salt thereof.

15 2. A glucopyranosyloxypyrazole derivative as claimed in claim 1, represented by the general formula:




wherein R^{11} represents a hydrogen atom or a straight-chained or branched alkyl group having 1 to 3 carbon atoms; one of Q^{11} and T^{11} represents a group represented by the formula:

20




while the other represents a straight-chained or branched alkyl group having 1 to 3 carbon atoms; and R^{21} represents a straight-chained or branched alkyl group having 1 to 4 carbon atoms, a straight-chained or branched alkoxy group having 1 to 3 carbon atoms or a straight-chained or branched alkylthio group having 1 to 3 carbon atoms, or a pharmaceutically acceptable salt thereof.

3. A glucopyranosyloxypyrazole derivative as claimed in claim 1, represented by the general formula:



wherein R^{12} represents a hydrogen atom, an ethyl group, a propyl group or an isopropyl group; one of Q^{12} and T^{12} represents a group represented by the formula:



while the other represents a methyl group; and R^{22} represents an ethyl group, an ethoxy group, an isopropoxy group or a methylthio group, or a pharmaceutically acceptable salt thereof.


4. A pharmaceutical composition comprising as an active ingredient a glucopyranosyloxypyrazole derivative as claimed in claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition as claimed in claim 4 wherein the composition is a human SGLT2 inhibitor.

6. A pharmaceutical composition as claimed in claim 4 wherein the composition is an agent for the prevention or treatment of diabetes.

7. A pharmaceutical composition as claimed in claim 4 wherein the composition is an agent for the prevention or treatment of obesity.

8. A glucopyranosyloxypyrazole derivative represented by the general formula:




20

wherein R^1 represents a hydrogen atom or a lower alkyl group; one of Q^2 and T^2 represents a 2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy group, while the other represents a lower alkyl group or a halo(lower alkyl) group; and R^2 represents a

hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a salt thereof.

- 5 9. A benzylpyrazole derivative represented by the general formula:



- wherein $R^{2'}$ represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and $R^{3'}$ represents a lower alkyl group, or a salt thereof.
- 10